D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
HENDERSON, Nev. - Paysign, Inc. (NASDAQ: PAYS), a provider of payment processing services with a market capitalization of $235.3 million, announced an expansion with a major plasma collection company that will significantly increase its U.S. market share in plasma donor compensation programs. The company, which has demonstrated strong revenue growth of 26.77% over the last twelve months, will be adding 132 established plasma donation centers to its network.
The transition of these centers from the incumbent provider is currently in progress. Paysign expects to have 123 centers operational by the end of the second quarter of 2025, with the remaining nine centers following in the third quarter of the same year.
This expansion is set to increase Paysign’s support to over 615 plasma centers across 18 companies, marking a 27% growth in the number of centers it operates. As a result, the company’s U.S. market share is anticipated to reach approximately 50%. According to InvestingPro data, the company maintains a healthy gross profit margin of 57.92%, suggesting strong operational efficiency in its existing centers.
Mark Newcomer, President and CEO of Paysign, commented on the expansion, highlighting the company’s commitment to delivering scalable and innovative solutions to the plasma industry. The growth is expected to drive immediate revenue growth for Paysign’s plasma business segment.
Paysign also forecasts that the newly onboarded centers will achieve around 80% of the company’s average revenue per center shortly after the transition and are expected to contribute fully to revenues by the end of the first quarter of 2026. Notably, the company does not foresee an increase in Selling, General and Administrative (SG&A) expenses associated with the new centers, underscoring the operating leverage of its business model.
Paysign, Inc., established in 1995 and headquartered in southern Nevada, offers a range of financial technology products and integrated payment processing solutions for various industries, including pharmaceutical, healthcare, and retail. The company has maintained profitability over the last twelve months with positive earnings per share of $0.11, and analysts expect continued earnings growth in the coming year.
The information in this article is based on a press release statement from Paysign, Inc.
In other recent news, Paysign Inc. reported its first-quarter 2025 earnings, showcasing impressive financial performance. The company achieved a 41% year-over-year increase in revenue, reaching $18.6 million, and a remarkable 193% rise in adjusted EBITDA. Paysign’s earnings per share (EPS) of $0.05 significantly surpassed analyst expectations, which were forecasted at $0.01. Following the strong quarterly results, DA Davidson raised its price target for Paysign to $6.00 from $5.00, maintaining a Buy rating on the stock. The firm cited Paysign’s robust financial outcomes as the reason for the upgrade. Additionally, Paysign held its annual stockholders meeting, where all Board of Directors nominees were elected, and executive compensation was approved. The company also ratified Moss Adams LLP as its independent auditor for the upcoming fiscal year. Paysign’s strategic acquisition of Gamma Innovation is expected to enhance its offerings in the plasma market, contributing to its operational success.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.